Search research articles
Contact Us
Filters
Showing results (181-190 of 220) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
H-T Arkenau, R Plummer, L R Molife, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
D Mahadevan, R Plummer, M S Squires, et al.
Anti-Cancer Drug Design
|
September 1, 1995
Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)
R J Griffin, L C Pemberton, D Rhodes, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1993
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents
A L Jackman, G M Bisset, D I Jodrell, et al.
Cancer Treatment Reports
|
January 1, 1985
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer
I E Smith, S J Harland, B A Robinson, et al.
Seminars in Oncology
|
April 6, 1999
Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene
A H Calvert, S Ghokul, A Al-Azraqi, et al.
Anti-Cancer Drug Design
|
October 1, 1994
Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines)
C E Arris, C Bleasdale, A H Calvert, et al.
Cancer Research
|
October 1, 1989
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine)
I R Judson, A H Calvert, C J Rutty, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 220) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
H-T Arkenau, R Plummer, L R Molife, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
D Mahadevan, R Plummer, M S Squires, et al.
Anti-Cancer Drug Design
|
September 1, 1995
Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)
R J Griffin, L C Pemberton, D Rhodes, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1993
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents
A L Jackman, G M Bisset, D I Jodrell, et al.
Cancer Treatment Reports
|
January 1, 1985
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer
I E Smith, S J Harland, B A Robinson, et al.
Seminars in Oncology
|
April 6, 1999
Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene
A H Calvert, S Ghokul, A Al-Azraqi, et al.
Anti-Cancer Drug Design
|
October 1, 1994
Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines)
C E Arris, C Bleasdale, A H Calvert, et al.
Cancer Research
|
October 1, 1989
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine)
I R Judson, A H Calvert, C J Rutty, et al.
Page
of 22